PHILADELPHIA, April 21, 2023 (GLOBE NEWSWIRE) — Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced it has granted an inducement award to a new employee. Passage Bio granted options to purchase 82,000 shares of common…Read More
Passage Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635c4
